HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Accepted manuscript (PDF) All Versions of this Article: JME-09-0016v1 43/5/187    most recent Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Christiansen, J. Articles by Nielsen, F. Search for Related Content PubMed PubMed Citation Articles by Christiansen, J. Articles by Nielsen, F.

J Christiansen, Biology, University of Copenhagen, Copenhagen, Denmark
A Kolte, Clinical Biochemistry, Rigshospitalet, Copenhagen, Denmark
T Hansen, Clinical Biochemistry, Rigshospitalet, Copenhagen, Denmark
F Nielsen, Clinical Biochemistry, Rigshospitalet, Copenhagen, 2100, Denmark

Correspondence: Finn Nielsen, Email: finn.cilius.nielsen{at}rh.regionh.dk

Abstract

Recent genome-wide association (GWA) studies of type 2 diabetes have implicated insulin-like growth factor 2 mRNA-binding protein 2 (IMP2/IGF2BP2) as one of several factors in the aetiology of late onset diabetes. IMP2 belongs to a family of oncofetal mRNA-binding proteins implicated in RNA localization, stability and translation, that are essential for normal embryonic growth and development. This review provides a background to the IMP protein family with an emphasis on human IMP2, followed by a closer look at the GWA studies to evaluate the significance, if any, of the proposed correlation between IMP2 and type 2 diabetes.